Jul 15, 2008 - XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced that results from two ongoing Phase 1 studies of XOMA 052 in Type 2 diabetes will be presented at the 44th European Association for the Study of Diabetes (EASD) Annual Meeting that will be held in Rome, Italy on September 7-11, 2008. The oral presentation, titled "XOMA 052, an Anti-IL-1beta Antibody, in a Double-Blind, Placebo-Controlled, Dose Escalation Study of the Safety and Pharmacokinetics in Patients with Type 2 Diabetes Mellitus - A New Approach to Therapy" will examine safety and pharmacokinetics of XOMA 052 in addition to certain markers of activity such as hemoglobin A1c and C-reactive protein.
In the two studies, XOMA 052 was well tolerated without any evidence of serious drug-related adverse events. Clearance of XOMA 052 was consistent with that of a human antibody with a terminal half-life of 15-21 days. This drug profile, when combined with XOMA 052's high binding affinity of 300 femtomolar, could support potential dosing of once per month or longer in Type 2 diabetes patients... XOMA's Press Release -
